Skip to content

Clinical Study on Different Doses of Qingfei Dayuan Granule in The Treatment of Influenza

Clinical Study on Different Doses of Qingfei Dayuan Granule in The Treatment of Influenza

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004455
Enrollment
Unknown
Registered
2021-02-18
Start date
2021-02-18
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Sponsors

Hubei Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: To participate in the study, all of the following criteria are met: (1) It meets the clinical diagnostic criteria for influenza; (2) In line with the traditional Chinese medicine standard of heat toxicity to the lung; (3) Aged 18-70 years; (4) Fever duration <= 48h; Axillary temperature is 37.3 degrees or higher; (5) Rapid antigen detection of influenza virus in throat swab was positive; Informed consent process in accordance with the regulations, signed the informed consent.

Exclusion criteria

Exclusion criteria: You may not participate in the study if you: (1) Severe or critical cases of influenza, or diagnosed as Covid-19, pharyngeal conjunctive membrane fever, herpetic pharyngitis, suppurative tonsillitis, etc.; (2) Complications of influenza such as sinusitis, otitis media and pneumonia; (3) The anti-influenza drugs included in the "Influenza Diagnosis and Treatment Plan (2020 Edition)" have been used within 48 hours before the visit; (4) Systematically receiving steroid therapy or other immunosuppressive therapy; (5) Have a history of epilepsy or febrile convulsions; (6) Patients with severe malnutrition, rickets and complicated with heart, brain, liver, kidney and hematopoietic system serious primary diseases; (7) Pregnant or lactating women with allergies, allergies to multiple drugs, or allergies to known ingredients of the study drug; According to the researchers' judgment, there are other lesions or conditions that reduce the possibility of inclusion or complicate inclusion, such as unstable living environment, inconvenient transportation and other conditions that are easy to cause loss of follow-up.

Design outcomes

Primary

MeasureTime frame
Complete antipyretic time;

Secondary

MeasureTime frame
Therapeutic effect of TCM syndromes;The rate of individual symptom disappearance, the time required for disappearance or remission;laboratory inspection;The incidence of complications/severe/critical influenza;Influenza antigen negative conversion rate;

Countries

China

Contacts

Public ContactBa Yuanming

Hubei Provincial Hospital of Traditional Chinese Medicine

1723426138@QQ.COM+86 13871013338

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026